JUBLPHARMA1,026.00

Jubilant Pharmova Ltd.

· Pharma & Health
₹ CrorePeersGLANDPPLPHARMAKIMSINDGNONESOURCEGRANULESPFIZERPOLYMEDMcap ₹16,211 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation381.9368.6440.4
+ Finance Costs272.3240.3211.8
+ Interest Income-26.1-36.6-25.2
+ Fair Value (Gains) / Losses-0.21.7-3.1
+ Share-based Payments8.54.311.8
+ Unrealised FX (Gain) / Loss1.40.1-6.4
+ Other Non-cash Items141.7-360.847.6
+ Other — Cash Effects are Investing / Financing0.00.05.5
Changes in Working Capital
+ Inventories90.878.5-44.9
+ Trade Receivables — Current49.424.2-99.5
+ Other Current Assets56.8-29.2-5.2
+ Trade Payables — Current23.255.3109.9
+ Other Current Liabilities32.9-17.0179.1
Cash from Operating Activities
Profit Before Tax (per I/S)146.4981.1614.4546.3
+ Total Adjustments (incl. Working Capital)1,032.6329.4821.8
Cash from Operations (pre-tax)1,179.01,310.51,436.2
+ Income Taxes Paid207.7238.4209.4
Cash from Operating Activities971.31,072.11,226.8
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)897.71,115.61,449.1
+ Disp of Fixed Assets9.75.0102.1
+ Purchase of Investments (Equity / Debt)7.81.40.0
+ Sale of Investments (Equity / Debt)5.7952.10.0
+ Government Grants Received229.9609.579.3
+ Interest Received — Investing25.738.424.4
+ Other Inflows / (Outflows) — Investing26.6-0.3-16.7
Cash from Investing Activities-607.9487.7-1,260.0
Cash from Financing Activities
+ Proceeds from Exercise of Stock Options0.00.90.0
+ Buyback / Redemption of Own Shares0.05.60.0
+ Proceeds from Borrowings117.227.42,571.3
+ Repayment of Borrowings137.61,100.42,069.7
+ Payment of Lease Liabilities61.259.870.9
+ Interest Paid243.7235.6238.3
+ Dividends Paid79.879.679.5
+ Other Inflows / (Outflows) — Financing-27.40.0-18.0
Cash from Financing Activities-432.5-1,452.794.9
Net Changes in Cash (pre-FX)-69.1107.161.7
+ Effect of FX Rate Changes on Cash11.624.8117.1
Net Changes in Cash-57.5131.9178.8
Closing Cash956.41,088.31,267.1
Reference Items
EBITDA900.81,173.71,259.81,218.2
EBITDA Margin %13.4416.2215.2214.15
Free Cash Flow (CFO − Capex)73.6-43.5-222.3-222.3
Free Cash Flow to Equity-1,256.3322.0
Free Cash Flow per Basic Share4.66-2.75-14.07-14.07
Cash Flow to Net Income13.361.283.09
Cash Paid for Taxes207.7238.4209.4
Cash Paid for Interest243.7235.6238.3
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.